34 results about "Withaferin A" patented technology

The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from Withania somnifera (Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.) (preferably 60% alcohol and 40% water) for the dry plant material and from 60% to 80% alcohol in the alcohol-water mixture for fresh plant material, the invented extractant composition leading to better / improved yields and accurate quantitative estimations of withaferin A existent in planta or in materia, selecting effective state of the tissue particularly use of the fresh materials improving yields, providing logistic benefits of isolations and diagnosis, and according several other advantages including technological, economic, preventing contaminations etc., the said method being valuable and advantageous for standardization of botanicals, metabolomic characterization of plants particularly chemotypes, analyzing metabolic transitions under physiological, genetical, environmental and biotic perturbations.

Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize cytokine-induced cell death and improve survival of transplanted islets. The method of the present invention involves identifying a subject having islet cells in need of treatment; and providing a effective amount of a Withaferin A composition disposed in a pharmaceutically acceptable carrier in an amount sufficient to reduce the inflammation after cytokine exposure without affecting the viability and potency of the islet cell population.

Weight loss agents include compounds defined by Formula I or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is Withaferin A. In other embodiments, the compound is Michael addition product of Withaferin A. The compounds can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof.

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.

A method for prevention and / or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV / TV %) by 3 folds as compared to free Withaferin A (WFA).

It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves.The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.

Described is a natural product-containing supplement that enhances intracellular concentration of bioactive molecules through inhibition of MDR efflux pumps. Specifically described are dosage forms for administration to a subject, the dosage forms having at least four ingredients selected from the group consisting of apigenin, cannabidiol, chrysin, harmine, caffeic acid, piperine, nobiletin, Hypericum perforatum extract, bee propolis, oleanolic acid, biochanin, luteolin, vanillin, honokiol, pterostilbene, and withaferin A. Upon administration to a mammalian subject, the dosage forms generally inhibit mis-regulated MDR efflux pumps that are responsible for pushing out good nutrients from the cell—thus increasing intracellular concentration of health-promoting compounds.

The invention provides a composition containing withaferin A, and relates to the technical field of medicines. The composition comprises topiramate and the withaferin A in a mass ratio of (1-25)*10<3>:1. Through the combined application of the topiramate and the withaferin A, the using amount of the topiramate and the withaferin A can be reduced, the side effects of the topiramate and the withaferin A can be obviously reduced, and the effects of reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism more significantly can be achieved. The composition can still achieve the effects of significantly reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism when the dosage is halved.

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.

Described herein is a process of genetic transformation in W. somnifera by Agrobacterium tumefaciens mediated transformation to overexpress squalene synthase gene (WsSQS) encoding WsSQS enzyme that catalyzes the synthesis of squalene from farnesyl pyrophosphate. Increased withanolide level including withaferin-A, withanolide A and B and withanone is attained in transformed plant tissues.

The invention provides a medicinal composition containing withaferin A and an application thereof, which belong to the technical fields of medical science and biology. The medicinal composition comprises withaferin A and quercetin, the mass ratio of the withaferin A to quercetin is 1: (1 to 1500). In the present invention, the medicinal composition is possible to prevent and treat neurodegenerative diseases, protects neurons, improves the distribution and morphology of tyrosine hydroxylase-positive neurons in the mass ratio of withaferin A to quercetin, treats neuroinflammation, not only significantly reduces the usage dosage, but also achieves better results than single usage.